In the global field of cognitive enhancer and neuroprotective drug development, Raw Noopept Powder (CAS 157115-85-0) has become a benchmark product among synthetic peptide nootropic ingredients due to its ultra-high activity, unique mechanism of action, and broad application potential. Developed by the Russian Institute of Pharmacology in the 1990s, initially designed as a potent alternative to piracetam, Raw Noopept Powder has rapidly surpassed traditional nootropic drugs and become a focus of scientific research and health fields due to its advantages such as small molecular weight, high lipid solubility, easy crossing of the blood-brain barrier, and excellent oral bioavailability. Compared with traditional drugs such as piracetam, it has approximately 1000 times higher activity, faster onset of action, longer duration of action, and lower dosage, while also possessing multiple effects including cognitive enhancement, neuroprotection, mood regulation, and anti-fatigue. From basic laboratory research to clinical applications, and then to the development of health foods and brain health products, Raw Noopept Powder has built a complete chain of scientific evidence, demonstrating irreplaceable value in areas such as mild cognitive impairment, brain injury repair, prevention of neurodegenerative diseases, and improvement of cognitive fatigue.
The "phenylacetylation code" of a dipeptide backbone
Raw Noopept Powder is chemically N-phenylacetyl-L-prolyl glycine ethyl ester, a synthetic dipeptide derivative. It is not a traditional polypeptide but a structurally optimized small-molecule neuroactive compound with the molecular formula C₁₇H₂₂N₂O₄ and a molecular weight of 318.37 g/mol. Its molecular structure consists of three core segments: a phenylacetyl group at one end, an L-proline residue in the middle, and a glycine ethyl ester segment at the other end. These three segments are covalently linked by amide bonds, forming a compact and rigid molecular backbone. This unique structure is the basis for its high activity, high bioavailability, and strong central nervous system penetration, and is a key characteristic distinguishing it from traditional nootropic drugs such as piracetam.
Structure-activity relationship analysis reveals that the Raw Noopept Powder's structural design is highly targeted: the phenylacetyl fragment imparts moderate lipophilicity, enabling rapid penetration of the intestinal mucosa and blood-brain barrier, achieving effective brain concentrations within 15-20 minutes after oral administration; the five-membered ring structure of the L-proline residue forms the core active backbone of the molecule, its spatial conformation highly compatible with the binding pockets of various receptors in the central nervous system, serving as a key site for activating neural signaling pathways; the glycine ethyl ester fragment enhances molecular stability and water solubility, while releasing the active metabolite cycloprolylglycine, an endogenous neuropeptide, after hydrolysis by esterases in vivo, which has been proven to be the core active form for the Raw Noopept Powder's long-lasting effect. Furthermore, the overall molecule is electrically neutral and has a small molecular weight, meeting the ideal physicochemical characteristics for drug penetration across the blood-brain barrier and avoiding the drawbacks of large peptide molecules being easily enzymatically degraded and difficult to penetrate the brain.
In terms of physicochemical properties, pharmaceutical-grade Raw Noopept Powder is a white to off-white crystalline powder, odorless, bitter in taste, and exhibits good flowability and stability. Its melting point is approximately 146-148℃, and it exhibits good solubility in water, ethanol, and dimethyl sulfoxide, solving the problem of poor water solubility in most natural nootropic components. The molecule is insensitive to light, temperature, and humidity, and can be stably stored for more than 2 years under normal temperature, dry, and light-protected conditions with a purity decrease of no more than 1%, fully meeting the storage and processing requirements of pharmaceutical raw materials. In industrial production, Raw Noopept Powder is prepared through chemical synthesis: acylation, condensation, purification, crystallization, drying, and pulverization processes yield a high-purity powder product. Pharmaceutical-grade products typically have a purity ≥99%, requiring strict control of single impurity content ≤0.5%, and indicators such as heavy metals, residue on ignition, microbial limits, and solvent residues must comply with ICH and Chinese Pharmacopoeia standards. Structural identification employs methods such as infrared spectroscopy, proton/carbon NMR spectroscopy, high-performance liquid chromatography, and mass spectrometry, accurately confirming structural integrity through characteristic peaks and retention times to ensure uniform and stable raw material quality.
Overall, the molecular structure of Raw Noopept Powder is a model of rational pharmaceutical design: by precisely splicing small molecule active fragments, it achieves four core advantages: high activity, high brain penetration, high stability, and low dosage. This overcomes the bottlenecks of easy degradation and poor absorption of natural neuropeptides, while avoiding the shortcomings of traditional synthetic nootropic drugs, such as low activity, high dosage, and significant side effects. Its structure is highly homologous to the endogenous neuropeptide CPG, endowing it with excellent biocompatibility and safety. At the same time, its artificially synthesized structure ensures controllable purity, stable quality, and large-scale industrial production. These structural characteristics establish Raw Noopept Powder's leading position in the field of nootropic raw materials, making it a high-quality pharmaceutical raw material that combines scientific rationality and industrial feasibility.
Diverse applications from cognitive impairment to neurodegenerative diseases
Raw Noopept Powder, a potent ingredient with both cognitive-enhancing and neuroprotective functions, has applications spanning multiple fields including pharmaceuticals, clinical nutrition, health foods, and brain health functional foods. Its applicability extends from disease treatment to cognitive enhancement in healthy individuals, making it one of the few multifunctional neuroactive ingredients covering both therapeutic and health-promoting areas. In the pharmaceutical field, it has been approved in countries such as Russia for the treatment of mild cognitive impairment, post-traumatic brain injury syndrome, and sequelae of cerebrovascular diseases. Globally, it is widely used in health foods and dietary supplements to address issues such as memory decline, poor concentration, cognitive fatigue, anxiety, and brain aging. Suitable populations include students, working professionals, the elderly, and those recovering from brain injuries. Its core value lies in its "low dosage, rapid onset of action, comprehensive effects, and long-lasting effects." A daily dose of only 10-30 mg can achieve significant improvements in brain function, far lower than the hundreds of milligrams required by traditional nootropic drugs.
In the field of cognitive enhancement and brainpower improvement, Raw Noopept Powder is the most widely used and recognized, with core efficacy covering five dimensions: learning, memory, attention, thinking speed, and information processing ability. Its effects on memory are comprehensive and precise: it enhances short-term working memory, strengthens long-term memory consolidation and retrieval, and improves spatial and logical memory. Animal experiments show that Raw Noopept Powder can increase the accuracy of maze learning in rats by more than 40% and double the memory retention time. Human trials have confirmed that healthy adults taking 10-20 mg daily for 4 weeks experience a 25%-35% improvement in memory test scores, extended attention span, faster thinking speed, and significantly improved efficiency in handling complex tasks. For students, it can alleviate pre-exam memory stress and learning fatigue; for working professionals, it can alleviate cognitive exhaustion caused by high-intensity work and improve decision-making and creativity; for middle-aged and elderly people, it can delay age-related memory decline and maintain daily cognitive function.
In the fields of neuroprotection and brain injury repair, the clinical value of Raw Noopept Powder is increasingly prominent, becoming an important adjunct treatment ingredient for cerebrovascular diseases, traumatic brain injury, and neurodegenerative diseases. For ischemic stroke and sequelae of cerebrovascular disease, it can improve cerebral microcirculation, reduce ischemia-reperfusion injury, protect neurons, and promote neurological function repair. Clinical studies show that stroke patients taking 20 mg daily for 3 months experience a reduction of more than 40% in neurological deficit scores, and significant improvements in limb motor, language, and cognitive functions. For traumatic brain injury and concussion, Raw Noopept Powder can reduce cerebral edema, inhibit inflammatory responses, reduce neuronal apoptosis, accelerate neuroplasticity reconstruction, shorten the rehabilitation period, and alleviate sequelae such as headache, dizziness, memory loss, and emotional instability. For Alzheimer's disease and mild cognitive impairment, it can reduce β-amyloid protein deposition, inhibit tau protein hyperphosphorylation, improve synaptic function, and delay the cognitive decline process. After taking it, MCI patients experience a 50% slowdown in the rate of cognitive score decline and maintain daily living abilities for a longer period.
In the fields of mood regulation, anxiety reduction, and fatigue relief, Raw Noopept Powder exhibits a unique "co-cognitive-mood synergistic improvement" effect, distinguishing it from simple sedative-type anti-anxiety drugs. It alleviates chronic stress and anxiety by regulating the levels of central neurotransmitters and neurotrophic factors, improving emotional stability and psychological resilience without causing side effects such as drowsiness, dizziness, or dependence. Clinical trials show that patients with cognitive impairment and anxiety experience a 30%-40% reduction in anxiety scores after taking Raw Noopept Powder, along with significant improvements in cognitive function, achieving a dual effect of "brain health + mood stabilization." Furthermore, it has a clear anti-central fatigue effect, relieving brain fatigue, lethargy, and slow reaction time caused by prolonged mental work, staying up late, and stress, while boosting energy and vitality. Its anti-fatigue effect lasts for 8-12 hours without the drawbacks of central stimulant components such as palpitations, insomnia, or rebound fatigue.
Neuroinflammation, alcohol addiction and its underlying mechanisms
The development of novel formulations and targeted delivery systems is currently the core research direction, aiming to further improve the bioavailability, brain targeting, and duration of action of Raw Noopept Powder. Although its oral absorption is good, some first-pass metabolism and uneven distribution in the brain still exist. To address this, researchers have developed several novel formulations: First, nano-formulations, reducing the particle size to 100-500 nm, improve intestinal absorption and blood-brain barrier penetration, with animal experiments showing a 2-4 fold increase in brain concentration and a duration of action extended to 12-16 hours; second, sustained-release formulations, enabling once-daily dosing, stable drug release, avoiding fluctuations in blood drug concentration, and improving compliance and long-lasting effects; third, nasal/transdermal formulations, bypassing the blood-brain barrier and liver first-pass, directly penetrating the central nervous system and target tissues through the nasal mucosa or skin, resulting in faster onset of action and higher local concentrations; fourth, prodrug and derivative formulations, synthesizing prodrugs through ester and peptide bond modification, releasing the active form through specific enzymatic decomposition in the brain, improving targeting and stability. These formulation innovations will significantly expand the application of Raw Noopept Powder in areas such as acute brain injury, Alzheimer's disease, and childhood cognitive impairment.
Structural optimization and the development of highly active derivatives aim to overcome existing molecular limitations and develop novel compounds with stronger activity, higher selectivity, and better drug-like properties. Research directions include: fluorination and methylation modification to enhance molecular lipophilicity and receptor affinity; in vitro experiments show that some derivatives exhibit 5-10 times increased activity; cyclization and heterocyclic modification to stabilize molecular conformation and enhance selectivity for TrkB and AMPA receptors; and peptide chimerism to fuse with brain-targeting peptides and antioxidant peptides, achieving dual functionality and precise targeting. Simultaneously, AI-based molecular docking and virtual screening technologies rapidly predict the binding activity of Raw Noopept Powder derivatives to targets, accelerating the development of novel drug molecules.
Synthetic biology and green manufacturing technologies are cutting-edge directions in industry, addressing the environmental and cost issues of traditional chemical synthesis. Traditional synthesis relies on organic reagents and multi-step reactions, posing pollution and safety risks. In recent years, genetically engineered E. coli and yeast have been used to construct cell factories to synthesize key intermediates of Raw Noopept Powder through biocatalysis and fermentation, followed by enzymatic condensation to obtain the final product. This technology offers mild reaction conditions, fewer byproducts, high purity, and a 30%-50% cost reduction, aligning with the trend towards green pharmaceuticals. Furthermore, the application of continuous flow synthesis and membrane separation purification technologies automates and simplifies the production process, improving product quality stability and production efficiency.
Conclusion
Based on a comprehensive analysis of its molecular structure, mechanism of action, clinical applications, industry status, and cutting-edge research, Raw Noopept Powder, as a benchmark product of synthetic dipeptide derivatives, represents a groundbreaking achievement in the integration of neuroscience and medicinal chemistry. Grounded in rational structural design, it overcomes the limitations of both natural neuropeptides and traditional nootropic drugs, achieving core advantages such as "ultra-high activity, high efficacy at low doses, rapid brain absorption, long-lasting stability, and safety and gentleness." This constructs a comprehensive efficacy system covering "cognitive enhancement, neuroprotection, mood regulation, anti-fatigue, and brain repair." From a mechanism of action perspective, it activates the BDNF/NGF neurotrophic pathway, optimizes neurotransmitter transmission, exerts antioxidant and anti-inflammatory effects, and enhances neuroplasticity, forming a complete regulatory network from molecular to functional levels. This makes it suitable for both acute cognitive enhancement and long-term brain health maintenance and delaying neurodegeneration. From an application perspective, it spans three major areas: pharmaceutical treatment, clinical rehabilitation, and health prevention, covering a wide range of populations including students, working professionals, the elderly, and brain injury patients. Its indications extend from mild cognitive impairment to neurodegenerative diseases, mental illnesses, and post-COVID-19 brain aerosols, continuously expanding its application boundaries. From an industrial value perspective, its synthesis process is mature, quality and cost are controllable, and its safety is high, meeting the rapidly growing global demand for brain health products and becoming a core raw material for health foods, functional foods, and innovative drug development.
Although Raw Noopept Powder has demonstrated remarkable efficacy and broad prospects, it still faces challenges such as the need for further refinement of some clinical evidence, insufficient segmentation of precise indications, and the need to promote the industrialization of novel formulations. With the deepening of neuroscience research, the conduct of large-scale clinical trials, breakthroughs in formulation technology, and the development of precision medicine, these problems are gradually being resolved, and its clinical value and industrial status will be further enhanced. Compared with traditional nootropic drugs, Raw Noopept Powder's multi-pathway synergistic mechanism is more in line with the needs of complex brain function regulation, and its safety and tolerability are more suitable for long-term use, which is in line with the development concept of modern medicine of "precision, gentleness, long-term effect, and overall regulation".
Xi'an Faithful Biotechnology Co., Ltd. offers high-quality Raw Noopept Powder with a purity of up to 99% (CAS 157115-85-0). For more details, please email allen@faithfulbio.com.
References
- Ostrovskaya, R. U., Gruden, M. A., Bobkova, N. V., Sewell, R. A., Gudasheva, T. A., Samokhin, A. N., Seredenin, S. B., Noppe, W., & Morozova-Roche, L. A. (2007). The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. Journal of Psychopharmacology, 21(6), 611–619.
- Ostrovskaya, R. U., Belnik, A. P., & Storozheva, Z. I. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bulletin of Experimental Biology and Medicine, 146(3), 334–337.
- Jia, X., Sun, Y., Li, Y., Zhang, Y., & Yan, J. (2011). Neuroprotective and nootropic drug noopept rescues α-synuclein amyloid cytotoxicity. Journal of Molecular Biology, 414(5), 699–712.
- Antipova, T. A., Gudasheva, T. A., & Seredenin, S. B. (2016). Dipeptide Piracetam Analogue Noopept Improves Viability of Hippocampal HT-22 Neurons in the Glutamate Toxicity Model. Bulletin of Experimental Biology and Medicine, 161(5), 58–61.
- Neznamov, G. G., & Teleshova, E. S. (2009). Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neuroscience & Behavioral Physiology, 39(7), 719–723.
- Pelsman, A., Hoyo-Vadillo, C., Gudasheva, T. A., & Seredenin, S. B. (2003). GVS-111 prevents oxidative damage and apoptosis in normal and Down syndrome human cortical neurons. International Journal of Developmental Neuroscience, 21(3), 117–124.
- Kondratenko, R. V., Povarov, I. S., Kolbaev, S. N., Derevyagin, V. I., Ostrovskaya, R. U., Gudasheva, T. A., & Seredenin, S. B. (2002). Anti-inflammatory properties of noopept (dipeptide nootropic agent GVS-111). Eksp Klin Farmakol, 65(2), 53–55.